Gensight Biologics SA
PAR:SIGHT
Gensight Biologics SA
Other Current Liabilities
Gensight Biologics SA
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gensight Biologics SA
PAR:SIGHT
|
Other Current Liabilities
€3.8m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
96%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Other Current Liabilities
€25.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innate Pharma SA
PAR:IPH
|
Other Current Liabilities
€4.3m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
16%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Other Current Liabilities
€17.2m
|
CAGR 3-Years
147%
|
CAGR 5-Years
44%
|
CAGR 10-Years
12%
|
|
|
Inventiva SA
PAR:IVA
|
Other Current Liabilities
€2.2m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Other Current Liabilities
€21.4m
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
24%
|
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
See Also
What is Gensight Biologics SA's Other Current Liabilities?
Other Current Liabilities
3.8m
EUR
Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Other Current Liabilities amounts to 3.8m EUR.
What is Gensight Biologics SA's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
96%
Over the last year, the Other Current Liabilities growth was 896%. The average annual Other Current Liabilities growth rates for Gensight Biologics SA have been -17% over the past three years , 96% over the past five years .
You don't have any saved screeners yet